|
1. Malpas JS, Bergsagel DE, Kyle RA, et. al. Myeloma: biology and management. Saunders, Elsevier Inc, USA. 2004.
2. Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 1992; 6:225.
3. http://www.cancer.org/docroot/CRI/CRI_2x.asp?sitearea=LRN&dt=30
4. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000; 355:248.
5. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21.
6. Silvestris F, Cafforio P, Calvani N, Dammacco F. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol 2004; 126:475.
7. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005; 16:1223.
8. Jacoby RF, Cole CE. Molecular diagnostic methods in cancer genetics. In: Abeloff MD, et al., eds. Clinical oncology. 2d ed. New York: Churchill Livingstone, 2000:119.
9. Cohen DJ, Sherman WH, Osserman EF, et. al. Acute renal failure in patients with multiple myeloma. Am J Med 1984; 76:247.
10. http://www.nkdep.nih.gov/
11. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749.
12. Rajkumar SV, Dispenzieri A, Fonseca R, et. al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001;15:1274.
13. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undertermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 2006; 81:693.
14. Møller-Petersen J, Schmidt EB. Diagnostic value of the concentration of M-component in initial classification of monoclonal gammopathy. Scand J Haematol 1986; 36:295.
15. Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 1999; 13:1259.
16. Drayson M, Tang LX, Drew R, et. al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97:2900.
17. Rajkumar SV, Kyle RA, Therneau TM, et. al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS). Blood 2005; 106: 812.
18. Bataille R, Durie BGM, Grenier J: Serum beta 2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol 1983; 55:439.
19. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23:3412.
20. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2001. Bethesda, MD, National Cancer Institute, 2004.
|